The healthcare vertical is US-focused, has 35-plus clients and 24,000 employees across 34 locations in five countries
Deal signed with AOP Orphan for US commercial rights
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
The product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients
The transaction is expected to close in the Q4FY22
Centre at Sree Chitra Tirunal Institute for Medical Sciences and Technology
MitraClip implants give a new lease of life for frail and elderly patients who cannot go in for conventional open-heart surgery
It is part of the company’s pain/analgesics portfolio of OTC products
Five seats reserved for Wards of COVID warriors in central MBBS admission
It is designed to tackle mental health issues
Subscribe To Our Newsletter & Stay Updated
